Clinical Trial Detail

NCT ID NCT02502266
Title Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube cancer

peritoneum cancer

ovarian cancer

Therapies

Topotecan

Paclitaxel

Doxorubicin

Olaparib

Cediranib

Age Groups: adult

No variant requirements are available.